AR065335A1 - Combinaciones de agentes terapeuticos para el tratamiento de cancer - Google Patents
Combinaciones de agentes terapeuticos para el tratamiento de cancerInfo
- Publication number
- AR065335A1 AR065335A1 ARP080100618A ARP080100618A AR065335A1 AR 065335 A1 AR065335 A1 AR 065335A1 AR P080100618 A ARP080100618 A AR P080100618A AR P080100618 A ARP080100618 A AR P080100618A AR 065335 A1 AR065335 A1 AR 065335A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- kinase
- tyrosine
- kinase inhibitor
- protein
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 17
- 150000001875 compounds Chemical class 0.000 abstract 7
- 229940043355 kinase inhibitor Drugs 0.000 abstract 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 5
- 108091000080 Phosphotransferase Proteins 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 4
- 102000020233 phosphotransferase Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 abstract 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 abstract 2
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 abstract 1
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 abstract 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 abstract 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 abstract 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 abstract 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 abstract 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 abstract 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 abstract 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 abstract 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 abstract 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102400001368 Epidermal growth factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 229940122588 Heparanase inhibitor Drugs 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229940113306 Ligase inhibitor Drugs 0.000 abstract 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 abstract 1
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 1
- 239000012819 MDM2-Inhibitor Substances 0.000 abstract 1
- 229940124647 MEK inhibitor Drugs 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 abstract 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 abstract 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 abstract 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 abstract 1
- 108091008606 PDGF receptors Proteins 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 108010039230 Protein Kinase C-delta Proteins 0.000 abstract 1
- 102100037340 Protein kinase C delta type Human genes 0.000 abstract 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000014128 RANK Ligand Human genes 0.000 abstract 1
- 108010025832 RANK Ligand Proteins 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 abstract 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 abstract 1
- 101150046814 SAPK2 gene Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 102100023132 Transcription factor Jun Human genes 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003121 adenosine kinase inhibitor Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000004404 adrenal cortex Anatomy 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 230000000964 angiostatic effect Effects 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 230000000719 anti-leukaemic effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 239000003719 aurora kinase inhibitor Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 abstract 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229940045109 genistein Drugs 0.000 abstract 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 abstract 1
- 235000006539 genistein Nutrition 0.000 abstract 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000436 ligase inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 238000002428 photodynamic therapy Methods 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000003277 telomerase inhibitor Substances 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 1
- 230000006444 vascular growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinacion que comprende la N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-iI)-etil]-amino]-metil]-fenil]-2E-2-propenamida; y uno o más agentes farmacéuticamente activos; a composiciones farmacéuticas que comprenden esta combinacion; a métodos detratamiento que comprenden esta combinacion; a procesos para elaborar dicha combinacion; y a un paquete comercial que comprende la combinacion mencionada. Reivindicacion 1: Una combinacion de: (a) N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etiI]-amino]-metil]-fenil}-2E-2-propenamida; y (b) uno o más agentes farmacéuticamente activos seleccionados a partir del grupo que consiste en: Un inhibidor de la enzima convertidora de angiotensina, Un inhibidor de la cinasa de adenosina; Un adyuvante;Un antagonista de la corteza adrenal; Un inhibidor de la senda de AKT; Un agente alquilante; Un inhibidor de angiogénesis; Un esteroide angiostático; Un anti-androgeno; Un anti-estrogeno; Un agente anti-hipercalcemia; Un compuesto anti-leucémico; Unanti-metabolito; Un anticuerpo anti-proliferativo; Un inductor de apoptosis; Un antagonista del receptor AT1; Un inhibidor de la cinasa aurora; Un inhibidor de aromatasa; Un modificador de la respuesta biologica; Un bisfosfonato; Un inhibidor de lacinasa de tirosina de Bruton (BTK); Un inhibidor de calcineurina; Un inhibidor de la cinasa CaM II; Un inhibidor de la fosfatasa de tirosina CD45; Un inhibidor de la fosfatasa CDC25; Un inhibidor de CYP3A4; Un inhibidor de la cinasa CHK; Uncompuesto que dirige/reduce una actividad de cinasa de proteína o de lípido, o una actividad de fosfatasa de proteína o de lípido, un compuesto antiangiogénico adicional, o un compuesto que induce los procesos de la diferenciacion celular; Un agentede control para regular genisteína, olomucina, y/o tirfostinas; Un inhibidor de ciclo-oxigenasa; Un inhibidor de la cinasa cRAF; Un inhibidor de la cinasa dependiente de ciclina; Un inhibidor de la proteasa de cisteína; Un intercalador de ADN; Unrompedor de cadena de ADN; Un inhibidor de la ligasa E3; Un enlazador de EDG; Una hormona endocrina; Compuestos que dirigen, reducen, o inhiben la actividad de la familia del factor de crecimiento epidérmico; Un inhibidor de la cinasa de tirosinareceptora del factor de crecimiento epidérmico, y receptora del factor de crecimiento derivado de plaquetas; Un inhibidor de farnesil-transferasa; Un inhibidor de la cinasa Flk-1; Un compuesto que dirige, reduce, o inhibe la actividad de Flt-3; Unagonista de gonadorelina; Un inhibidor de la cinasa de sintasa de glicogeno-3 (GSK3); Un inhibidor de heparanasa; Un agente utilizado en el tratamiento de malignidades hematologicas; Un inhibidor de la desacetilasa de histona (HDAC); Un inhibidor deHSP90; Un implante que contiene corticosteroides; Un inhibidor de la cinasa l-Kappa B-alfa (IKK); Un inhibidor de la cinasa de tirosina receptora de insulina; Un inhibidor de la cinasa de cinasa N-terminal c-Jun (JNK); Un agente de enlace demicrotubulo; Un inhibidor de cinasa de proteína activada por mitogeno (MAP); Un inhibidor de MDM2; Un inhibidor de MEK; Un inhibidor amino-peptidasa de metionina; Un inhibidor del inhibidor de metaloproteinasa de matriz (MMP); Un anticuerpomonoclonal; Un inhibidor de la cinasa de tirosina NGFR; Un inhibidor de la cinasa MAP p38, incluyendo un inhibidor de la cinasa SAPK2/p38; Un inhibidor de la cinasa de tirosina p56; Un inhibidor de la cinasa de tirosina receptora del factor decrecimiento derivado de plaquetas; Un inhibidor de la cinasa de fosfatidil-inositol-3; Un inhibidor de fosfatasa; Terapia fotodinámica; Un agente de platino; Un inhibidor de la fosfata de proteína, incluyendo un inhibidor de PP1 y PP2, y uninhibidor de la fosfatasa de tirosina; Un inhibidor de la cinasa C de proteína, y un inhibidor de la cinasa delta de la cinasa C de proteína; Un inhibidor de la síntesis de poliamina; Un inhibidor de proteasoma; Un inhibidor de PTP1B; Un inhibidorde la cinasa de proteína tirosina, incluyendo un inhibidor de la cinasa de tirosina de la familia SRC; un inhibidor de la cinasa de tirosina Syk; y un inhibidor de la cinasa de tirosina JAK-2 y/o JAK3; Un inhibidor de las isoformas oncogénicas Ras;Un retinoide; Un inhibidor de la reductasa de ribonucleotido; Un inhibidor de elongacion de la polimerasa de ARN II; Un inhibidor de la descarboxilasa de S-adenosil metionina; Un inhibidor de la cinasa de serina/treonina; Un compuesto que dirige,reduce, o inhibe la actividad/funcion de la cinasa mTOR de serina/treonina; Un antagonista del receptor de sornatostatina; Un inhibidor de la biosíntesis de esterol; Un inhibidor de telomerasa; Un inhibidor de topoisomerasa; Planteamientos que dananlas células tumorales; Un anticuerpo monoclonal del factor de crecimiento endotelial vascular o del receptor del factor de crecimiento endotelial vascular; Un inhibidor de la cinasa de tirosina receptora del factor de crecimiento endotelialvascular; y Un inhibidor de RANKL; y una mezcla de los mismos; para su uso simultáneo, concurrente, separado, o en secuencia en la prevencion o el tratamiento de una enfermedad proliferativa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89000507P | 2007-02-15 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065335A1 true AR065335A1 (es) | 2009-06-03 |
Family
ID=39560929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100618A AR065335A1 (es) | 2007-02-15 | 2008-02-13 | Combinaciones de agentes terapeuticos para el tratamiento de cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US20100069458A1 (es) |
| EP (3) | EP2491923A3 (es) |
| JP (1) | JP2010519209A (es) |
| KR (1) | KR20090110913A (es) |
| CN (1) | CN101626758A (es) |
| AR (1) | AR065335A1 (es) |
| AU (1) | AU2008216327A1 (es) |
| BR (1) | BRPI0807812A2 (es) |
| CA (1) | CA2677651A1 (es) |
| CL (1) | CL2008000470A1 (es) |
| CO (1) | CO6220928A2 (es) |
| EC (1) | ECSP099576A (es) |
| IL (1) | IL200193A0 (es) |
| MA (1) | MA31205B1 (es) |
| MX (1) | MX2009008584A (es) |
| PE (1) | PE20090519A1 (es) |
| RU (1) | RU2009134223A (es) |
| TN (1) | TN2009000344A1 (es) |
| TW (1) | TW200848022A (es) |
| WO (1) | WO2008100985A2 (es) |
| ZA (1) | ZA200905159B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| EP2117598A2 (en) * | 2007-01-10 | 2009-11-18 | Novartis AG | Formulations of deacetylase inhibitors |
| JP2010520176A (ja) | 2007-03-01 | 2010-06-10 | ノバルティス アーゲー | ５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤 |
| CL2008002786A1 (es) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. |
| ME02230B (me) | 2009-01-08 | 2016-02-20 | Curis Inc | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| EP2557923A4 (en) * | 2010-04-16 | 2013-10-23 | Curis Inc | TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS |
| CN102241628B (zh) * | 2010-05-14 | 2015-11-25 | 中国人民解放军总医院 | (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途 |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| RU2013114246A (ru) * | 2010-09-01 | 2014-10-20 | Новартис Аг | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении |
| PE20141382A1 (es) | 2011-04-01 | 2014-11-04 | Curis Inc | Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc |
| WO2012149493A2 (en) * | 2011-04-28 | 2012-11-01 | Sloan-Kettering Institute For Cancer Research | Hsp90 combination therapy |
| NZ618367A (en) * | 2011-06-14 | 2016-01-29 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| US20130178483A1 (en) * | 2011-06-28 | 2013-07-11 | Pharmacyclics, Inc. | Methods and Compositions for Inhibition of Bone Resorption |
| CA2863679A1 (en) | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| CN102949722A (zh) * | 2011-08-26 | 2013-03-06 | 中国医学科学院放射医学研究所 | 基于p38抑制剂和细胞生长因子的新颖药物组合物 |
| WO2013070996A1 (en) | 2011-11-11 | 2013-05-16 | Novartis Ag | Method of treating a proliferative disease |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
| JP2016512549A (ja) * | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
| KR20160145833A (ko) * | 2014-05-02 | 2016-12-20 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법 |
| TWI735413B (zh) * | 2014-06-02 | 2021-08-11 | 國立陽明交通大學 | 抗藥性癌症之治療方法 |
| EP3154952A4 (en) * | 2014-06-10 | 2018-03-14 | University of South Carolina | Methods and compositions for treatment of her-positive cancers |
| MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| KR101941045B1 (ko) * | 2017-08-09 | 2019-01-22 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 약학적 조성물 |
| KR101988124B1 (ko) * | 2017-08-31 | 2019-06-11 | 사회복지법인 삼성생명공익재단 | 암 연관 섬유아세포 표적용 약학적 조성물 |
| PE20211050A1 (es) | 2018-08-10 | 2021-06-04 | Navire Pharma Inc | Inhibidores de ptpn11 |
| CA3112177A1 (en) | 2018-09-11 | 2020-03-19 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| CN115137716A (zh) * | 2021-04-19 | 2022-10-04 | 海军军医大学第一附属医院第二军医大学第一附属医院上海长海医院 | 紫草素及其药学上可接受的盐类在制备预防或治疗绝经后骨质疏松症药物中的应用 |
| CN118615291A (zh) * | 2024-04-19 | 2024-09-10 | 三峡大学 | 角鲨烯环氧酶新型抑制剂及其在制备治疗抗乳腺癌的药物上的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| EP2016953A3 (en) | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| EP1165085B1 (en) | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| RU2311200C2 (ru) * | 2001-11-06 | 2007-11-27 | Новартис Аг | Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы |
| CN1791396A (zh) * | 2003-05-21 | 2006-06-21 | 诺瓦提斯公司 | 组蛋白脱乙酰基酶抑制剂与化疗剂的组合 |
| EP1667720A1 (en) * | 2003-09-18 | 2006-06-14 | Novartis AG | Combination of a histone deacetylase inhibitor with a death receptor ligand |
| EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| BRPI0614090A2 (pt) * | 2005-08-03 | 2011-03-09 | Novartis Ag | uso de inibidores da hdac para o tratamento do mieloma |
-
2008
- 2008-02-13 EP EP12150317A patent/EP2491923A3/en not_active Withdrawn
- 2008-02-13 CN CN200880005098A patent/CN101626758A/zh active Pending
- 2008-02-13 AR ARP080100618A patent/AR065335A1/es unknown
- 2008-02-13 MX MX2009008584A patent/MX2009008584A/es not_active Application Discontinuation
- 2008-02-13 AU AU2008216327A patent/AU2008216327A1/en not_active Abandoned
- 2008-02-13 KR KR1020097016980A patent/KR20090110913A/ko not_active Withdrawn
- 2008-02-13 JP JP2009549693A patent/JP2010519209A/ja active Pending
- 2008-02-13 RU RU2009134223/15A patent/RU2009134223A/ru not_active Application Discontinuation
- 2008-02-13 CA CA002677651A patent/CA2677651A1/en not_active Abandoned
- 2008-02-13 WO PCT/US2008/053798 patent/WO2008100985A2/en not_active Ceased
- 2008-02-13 BR BRPI0807812-2A patent/BRPI0807812A2/pt not_active Application Discontinuation
- 2008-02-13 EP EP11157791A patent/EP2359818A1/en not_active Withdrawn
- 2008-02-13 EP EP08729719A patent/EP2120900A2/en not_active Withdrawn
- 2008-02-13 US US12/526,962 patent/US20100069458A1/en not_active Abandoned
- 2008-02-13 PE PE2008000314A patent/PE20090519A1/es not_active Application Discontinuation
- 2008-02-14 TW TW097105218A patent/TW200848022A/zh unknown
- 2008-02-14 CL CL200800470A patent/CL2008000470A1/es unknown
-
2009
- 2009-07-23 ZA ZA200905159A patent/ZA200905159B/xx unknown
- 2009-07-30 IL IL200193A patent/IL200193A0/en unknown
- 2009-08-13 EC EC2009009576A patent/ECSP099576A/es unknown
- 2009-08-13 CO CO09085032A patent/CO6220928A2/es not_active Application Discontinuation
- 2009-08-14 TN TNP2009000344A patent/TN2009000344A1/fr unknown
- 2009-08-31 MA MA32192A patent/MA31205B1/fr unknown
-
2012
- 2012-07-25 US US13/557,731 patent/US20130029927A1/en not_active Abandoned
-
2014
- 2014-12-08 US US14/563,430 patent/US20150094274A1/en not_active Abandoned
-
2016
- 2016-07-28 US US15/222,370 patent/US20170027909A1/en not_active Abandoned
-
2017
- 2017-05-17 US US15/597,718 patent/US20170246147A1/en not_active Abandoned
- 2017-11-14 US US15/812,141 patent/US20180071251A1/en not_active Abandoned
-
2018
- 2018-06-12 US US16/006,137 patent/US20180289670A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2491923A3 (en) | 2012-12-26 |
| US20170027909A1 (en) | 2017-02-02 |
| MX2009008584A (es) | 2009-08-18 |
| EP2120900A2 (en) | 2009-11-25 |
| US20130029927A1 (en) | 2013-01-31 |
| US20180289670A1 (en) | 2018-10-11 |
| US20150094274A1 (en) | 2015-04-02 |
| CN101626758A (zh) | 2010-01-13 |
| US20170246147A1 (en) | 2017-08-31 |
| KR20090110913A (ko) | 2009-10-23 |
| TW200848022A (en) | 2008-12-16 |
| JP2010519209A (ja) | 2010-06-03 |
| CA2677651A1 (en) | 2008-08-21 |
| ZA200905159B (en) | 2010-05-26 |
| WO2008100985A3 (en) | 2008-10-30 |
| EP2359818A1 (en) | 2011-08-24 |
| US20180071251A1 (en) | 2018-03-15 |
| CL2008000470A1 (es) | 2008-08-29 |
| EP2491923A2 (en) | 2012-08-29 |
| RU2009134223A (ru) | 2011-03-20 |
| ECSP099576A (es) | 2009-09-29 |
| TN2009000344A1 (en) | 2010-12-31 |
| CO6220928A2 (es) | 2010-11-19 |
| MA31205B1 (fr) | 2010-02-01 |
| IL200193A0 (en) | 2010-04-15 |
| US20100069458A1 (en) | 2010-03-18 |
| AU2008216327A1 (en) | 2008-08-21 |
| PE20090519A1 (es) | 2009-05-29 |
| BRPI0807812A2 (pt) | 2020-06-23 |
| WO2008100985A2 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065335A1 (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer | |
| Kumar et al. | Drug targets for cancer treatment: an overview | |
| Tomasi et al. | S‐adenosyl methionine regulates ubiquitin‐conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers | |
| Hennequin et al. | Biological basis for chemo-radiotherapy interactions | |
| Raju et al. | Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib | |
| Chan et al. | Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E2 in articular cartilage explants | |
| Yu et al. | Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression | |
| JP2023129662A (ja) | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 | |
| Simbulan-Rosenthal et al. | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma | |
| Gao et al. | The therapeutic significance of aromatase inhibitors in endometrial carcinoma | |
| JP2020505395A (ja) | 縮合ｎ−複素環式化合物およびその使用方法 | |
| Zhou et al. | Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| Yang et al. | SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo | |
| WO2018140512A1 (en) | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | |
| WO2004085418A3 (en) | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| JP2007505938A5 (es) | ||
| Ma et al. | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance | |
| Geisler et al. | Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? | |
| BRPI0417158A (pt) | composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| Li et al. | Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach | |
| NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |